Insider Buying: Amplia Therapeutics Limited (ASX:ATX) Insider Acquires 827,268 Shares of Stock

Amplia Therapeutics Limited (ASX:ATXGet Free Report) insider Robert Peach acquired 827,268 shares of Amplia Therapeutics stock in a transaction dated Wednesday, June 19th. The stock was purchased at an average cost of A$0.06 ($0.04) per share, for a total transaction of A$45,499.74 ($30,333.16).

Amplia Therapeutics Price Performance

The company has a quick ratio of 5.05, a current ratio of 3.43 and a debt-to-equity ratio of 15.18.

About Amplia Therapeutics

(Get Free Report)

Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other solid tumors and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for acute myeloid leukemia (AML) and certain solid tumors.It has a collaboration agreement with the Garvan Institute of Media Research in Sydney.

Read More

Receive News & Ratings for Amplia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amplia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.